Lab quality results in 10 minutes from

a finger-stick blood sample

Exhibit 99.2

Time and discomfort

for venous blood

draw

1-3 day delay in lab

results, diagnosis,

and treatment

Maintenance of

certifications

and lab quality

COST

PATIENT

CARE

Challenges of Obtaining Diagnostic Information

Real World Convenience

1-2

mins

10

mins

Stable and

contamination

free reagents

Sample collected

Cassette

activated by

vacuum

Analyzes results

Claros Microfluidic Assay Process

Seal

Seal

Seal

Cassette

Sangia™

Microfluidic Cassette

CONVENIENT

LAB QUALITY

ACCURACY

Single, self-contained cartridge

2

4

6

8

10

12

2

4

6

8

10

12

ng/mL

Sangia Total PSA

Roche Cobas central lab system

ng/mL

Elecsys PSA

EXCELLENT

CORRELATION

ensures

LAB QUALITY

RESULTS

IN-OFFICE

R  of 0.970

Proven Results

2

Claros 1 Update

•

Formulation of blood collector providing high reliability for results reporting

•

SMA Chemistry providing rapid attachment and low LOQ

•

Testosterone

–

FDA: Pre-submission comments received from FDA

–

On track to file 510(k) in 2014

–

CE Mark: 4Q2014

•

PSA

–

FDA: Pre-submission response expected in August

–

Timing of 510k submission based on longitudinal trial requirements

–

CE Mark Update (Formulation and Chemistry): 4Q2014

•

Vitamin D

–

On track to support launch of Rayaldee 1Q2016

Personal risk for high-grade prostate cancer

…from a blood test

The Issues of PSA Screening

Aiding Decision for Prostate Biopsy

Poor accuracy in distinguishing

cancers

PSA SCREENING

BIOPSY CANDIDATES

Peter Scardino

(MSKCC, New York)

Andrew Vickers

(MSKCC, New York)

Hans Lilja

(MSKCC/Malmö/Oxford)

Kim Pettersson

(Univ. of Turku, Finland)

International team of researchers

Rigorous Clinical Research

Monique Roobol

Netherlands

Angel Cronin

USA

Caroline Savage

USA

Fritz Schröder

Netherlands

Mari Peltola

Finland

Charlotte Becker

Sweden

Sigrid Carlsson

USA/Sweden

Gunnar Aus

Sweden

Carl-Gustav Pihl

Sweden

Amine Benchikh

France

Alexandra Mashino

USA

Arnauld Villers

France

Chris Bangma

Netherlands

Ewout Steyerberg

Netherlands

Theo van der Kwast

Netherlands

Daniel Sjoberg

USA

Jonas Hugosson

Sweden

Timo Lövgren

(Univ. of Turku, Finland)

Amit Gupta

USA

3

decades of

biomarker research

Over

10,000

men studied

9 cohorts in

peer-reviewed

publications

Results of each

biomarker

Digital rectal exam (DRE)

Prior biopsy

Age of patient

7 Elements of the 4Kscore Test

46 years 

53 years

65 years

68 years

Total PSA

Free PSA

Intact PSA

hK2

Kallikrein blood tests

37%

Negative or

Gleason

score

6

20%

Gleason

score

7

77%

Negative or

Gleason

score

6

23%

Gleason

score

7

9% cut off level

Number of

patients

1000

800

600

400

200

Current US practice

0

Replication of Performance in a US Cohort

26 Urology Centers

1,012 Patients

Prospective, Blinded

Clinical study sites

43%

Biopsies

avoided

Decrease Unnecessary Biopsies

Proven Results

Accurate Probability for

High-grade Cancer

4Kscore Test US Commercial Activities

•

Post AUA follow-ups with LUGPA, PI Sites, etc.

•

Test seeding program with select, regional urologists

•

Launch web and social media platform

•

Complete build out of a blood draw site network

•

Publication of US Clinical Study (in preparation)

•

Establish a US Speakers Bureau for local advisory board

meetings

•

Initiate Reimbursement process with private insurance,

CMS